期刊文献+

MiR-148a对氟伐他汀人体药代动力学特征的影响

Effect of miR-148a on the pharmacokinetic properties of fluvastatin in Chinese health subjects
原文传递
导出
摘要 目的研究人血浆中miR-148a的表达水平对人体内氟伐他汀药代动力学特征的影响。方法建立人血浆中氟伐他汀LC-MS/MS检测方法,比较miR-148a高表达组和低表达组间氟伐他汀人体药代动力学特征的差异。结果MiR-148a高表达组AUC_(0-12)、AUC_(0-∞)、C_(max)、V_(d)、CL分别为(775.61±136.59)ng·h·mL^(-1),(779.88±137.90)ng·h·mL^(-1),(727.56±150.61)ng·mL^(-1),(185.29±70.06)L,(52.81±9.92)L·h^(-1);miR-148a低表达组AUC_(0-12)、AUC_(0-∞)、C_(max)、V_(d)、CL分别为(520.53±122.11)ng·h·mL^(-1),(524.43±121.64)ng·h·mL^(-1),(457.86±103.56)ng·mL^(-1),(317.12±93.08)L,(79.48±16.25)L·h^(-1);miR-148a高表达组的AUC_(0-12)、AUC_(0-∞)、C_(max)明显高于低表达组,而CL、V_(d)低于低表达组。结论人血浆中miR-148a的表达水平与氟伐他汀药代动力学过程存在相关性。 Objective To investigate the effect of plasma miR-148a level on the pharmacokinetic properties of fluvastatin in Chinese health subjects.Methods To establish a method for the determination of fluvastatin in human plasma by LC-MS/MS.The human pharmacokinetic characteristics of fluvastatin were compared between the high expression group and the low expression group of miR-148a.Results The pharmacokinetic parameters AUC_(0-12),AUC_(0-∞),C_(max),V_(d) and CL of fluvastatin in miR-148a high expression group were(775.61±136.59)ng·h·mL^(-1),(779.88±137.90)ng·h·mL^(-1),(727.56±150.61)ng·mL^(-1),(185.29±70.06)L,(52.81±9.92)L·h^(-1).The pharmacokinetic parameters AUC_(0-12),AUC_(0-∞),C_(max),V_(d) and CL of fluvastatin in low expression group were(520.53±122.11)ng·h·mL^(-1),(524.43±121.64)ng·h·mL^(-1),(457.86±103.56)ng·mL^(-1),(317.12±93.08)L,(79.48±16.25)L·h^(-1).Compared with the miR-148a low-expression group AUC_(0-12),AUC_(0-∞),and C_(max) was significantly higher in the miR-148 a high-expression group but CL and V_(d)were lower in the miR-148 a high-expression group than the miR-148 a low-expression group.Conclusion The plasma miR-148a was related to the pharmacokinetics of fluvastatin in healthy Chinese subjects.
作者 靳高凤 李西 张红 夏春华 熊玉卿 JIN Gao-feng;LI Xi;ZHANG Hong;XIA Chun-hua;XIONG Yu-qing(Clinical Pharmacology Institute,Nanchang University,Nanchang 330006,Jiangxi Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2022年第2期151-154,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(81673506)。
关键词 微小RNA-148a 表达水平 健康受试者 氟伐他汀 药代动力学 miR-148a expression level health subjects fluvastatin pharmacokinetics
  • 相关文献

参考文献3

二级参考文献20

  • 1[1]Lee S, Kim JM, Chung CS, Cho K J, Kim JH. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients[J]. Arch Pharm Res, 2003; 26 (11): 967 -72
  • 2[2]eSchwarz UI. Clinical relevance of genetic polymorphisrms in the human CYP2C9 gene[J]. Eur J Clin Invest, 2003;33(2) :23 -30
  • 3[3]Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic RA. Genetic polymorphisms of cytochromes P450: CYP2C9,CYP2C19, and CYP2D6 in Croatian population[J]. Croat Med J, 2003;44(4) :425 - 8
  • 4[4]Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J]. Fundam Clih Pharmacol,2003; 17(3) :373 - 6
  • 5[5]Takahashi H, WilkinsonGR, Caraco Y, Muszkat M, Kim RB,Kashima T, et al. Population diffcrenees in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients [J]. Clin Pharmacol Ther, 2003; 73 (3): 253 - 63
  • 6[6]Xie HG, Prasad HC, Kim RB, and Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance[J]. Adv Drug Deliv Rev, 2002;54(10): 1257 - 70
  • 7[7]Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP,Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian Populations[J]. Pharmacogenetics, 1997 ;7(2): 103 - 113
  • 8[8]Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA,Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin,glipizide and in an individual homozygous for the CYP2C9 * 3allele[J]. Pharmacogenetics, 1999: 9(1): 71 - 80
  • 9[9]Van der Weide J, Steijns LS, van Weelden MJ, de Haan K.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement [J]. Pharmacogenetics, 2001; 11(4) :287 - 91
  • 10[10]Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J]. Clin Pharmacol Ther, 2002;72(6) :702 - 10

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部